Mirati Therapeutics Inc.
mirati.comTotal trials
50
Active
8
Phase 3
6
Total enrollment
6,279
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Pembrolizumab | — | — | — | — | 7 | ||
| Adagrasib | — | — | — | 7 | |||
| MRTX849 | — | — | — | 7 | |||
| Cetuximab | — | — | — | — | 3 | ||
| Docetaxel | — | — | — | — | 3 | ||
| Pemetrexed | — | — | — | — | 2 | ||
| mFOLFOX6 Regimen | — | — | — | — | — | 1 | |
| FOLFIRI Regimen | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| Adagrasib oral dose of 400 mg twice daily | — | — | — | — | — | 1 | |
| Chemotherapy: Pemetrexed | — | — | — | — | — | 1 | |
| Cisplatin/Carboplatin | — | — | — | — | — | 1 | |
| Afatinib | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Oxaliplatin | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 |
Next readouts
- 2023-12-30
- 2026-01-16
- 2026-06-01
- 2026-07-30
- 2026-12-31
- 2028-02-16
- 2029-09-07
- 2032-06-09
Top conditions
- Advanced Cancer8
- Metastatic Cancer5
- Healthy Adults5
- Malignant Neoplastic Disease4
- Advanced Solid Tumor4
- Myelodysplastic Syndromes3
- Advanced Malignancies2
- Leukemia2
Frequently asked questions about Mirati Therapeutics Inc.
- How many clinical trials does Mirati Therapeutics Inc. have on ClinicalTrials.gov?
- Mirati Therapeutics Inc. is listed as the lead sponsor on 50 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mirati Therapeutics Inc.'s trials are in Phase 3?
- 6 of Mirati Therapeutics Inc.'s trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Mirati Therapeutics Inc. focus on?
- Mirati Therapeutics Inc.'s most-studied conditions on ClinicalTrials.gov are Advanced Cancer, Metastatic Cancer, Healthy Adults, Malignant Neoplastic Disease, Advanced Solid Tumor.
- When are Mirati Therapeutics Inc.'s next clinical trial readouts?
- Mirati Therapeutics Inc. has 8 upcoming primary-completion readouts tracked here; the soonest is “Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation”, expected around 2023-12-30.